



Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507

Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com

May 14, 2019

Corporate Relationship Department
BSE Limited
Dalal Street, Fort
Mumbai – 400 001
Fax Nos.: 022-22723121 / 22723719

National Stock Exchange of India Ltd.
“Exchange Plaza”
Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 051
Fax Nos.: 022-26598120/ 26598237

Scrip Code: 500124

Scrip Code: DRREDDY-EQ

Dear Sirs,

Ref.: Your email dated May 13, 2019

Sub: Reply to clarification on news

This is with reference to your email dated May 13, 2019, seeking clarification of the media report appearing in Economic Times dated May 13, 2019, titled ‘Pharma stocks bleed as US states file lawsuit against generic drug firms’.

In this regard, please note that on May 10, 2019, the Attorney General of forty-nine U.S. States, the Commonwealth of Puerto Rico and the District of Columbia, filed a Complaint in the United States District Court for the District of Connecticut against twenty-one generic pharmaceutical companies (including Dr. Reddy’s U.S. subsidiary) and fifteen other individual defendants, with respect to 116 generic drugs. The complaint alleges that Dr. Reddy’s U.S. subsidiary and the other named defendants engaged in a conspiracy to fix prices and to allocate bids and customers in the United States in the sale of the drugs.

Dr. Reddy’s U.S. subsidiary is specifically named as a defendant with respect to five generic drugs (Ciprofloxacin HCL tablets, Glimepiride tablets, Oxaprozin tablets, Paricalcitol and Tizanidine), for an alleged “overarching conspiracy”.

All cases related to Attorney Generals’ law suits and certain private plaintiffs class action suits, including the above would be consolidated in the multi district litigation (MDL), *In re generics pharmaceuticals antitrust pricing litigation*.

We intend to vigorously defend against these allegations and are in the process of filing our response with the District Court of Connecticut. Currently, we do not foresee any material impact to our operations and consolidated results with respect to this matter.

This is for your information.

With regards,


Sandeep Poddar
Company Secretary